

Special Issue

Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management

Message from the Guest Editors

Although the universal hepatitis B virus (HBV) vaccination program has been successfully implemented for almost three decades in many countries, most HBV-related hepatocellular carcinomas (HCCs) occur in unvaccinated middle-aged and elderly adults. The titer of HBV core-related antigen (HBcrAg) reflecting the amount of HBV covalently closed circular DNA (ccc DNA) in the liver is related to HCC occurrence. Sero clearance of HBs antigen (HBsAg) is more crucial than HBV DNA negativity for the prevention of HCC. In addition, the first-line therapies with NAs such as entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) remains to be clarified. Therefore, we discuss recent findings of HBV markers related to HCC occurrence and prevention, and unsolved discussions and review the secondary current antiviral therapies for the prevention of HBV-related HCC.

Guest Editors

Dr. Soo Ryang Kim

Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan

Dr. Soo Ki Kim

Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan

Deadline for manuscript submissions

closed (28 February 2025)



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/166603

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.6 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).